MedTrace Logo

The University of Hong Kong Neurocognitive Disorder Cohort

NCT03275363 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2017-09-07

No results posted yet for this study

Summary

The HKU Neurocognitive Disorder (NCD) Cohort is a hospital-based, prospective, observational study of older HK Chinese adults with cognitive impairment, with a special focus on studying patients with subjective cognitive decline and mild cognitive impairment.

Conditions

Interventions

DIAGNOSTIC_TEST

Neurocognitive battery

Cognitive impairment status (SCD, MCI, dementia), HK-MoCA, Clinical Dementia Rating (CDR sum of squares), Geriatric Depression Scale (GDS-15), Neuropsychiatric Index (NPI), Barthel Index, Lawton's IADL, Life-Space Assessment, Mini-Nutrition Assessment (MNA), Quality of Life for Alzheimer's Disease (QoL-AD, patient and carer parts), frailty status (FRAIL scale), handgrip strength, walking speed, exercise status, sleep quality, Charlson comorbidity index (CCI, age-adjusted). NACC: Story recall, Benson's complex figure copy, colour trail test (black \& white), verbal fluency, digit forward and backward span.

DIAGNOSTIC_TEST

MRI

MRI: T1, T2, FLAIR, SWI, DTI, fMRI, ASL, MRS, for selected patients

BIOLOGICAL

Blood tests

Stored samples (unanalysed): serum, plasma, buffy coat (PBMC); also processed for microvesicles and exosome analysis

DIAGNOSTIC_TEST

EEG with event-related potential (ERP)

128-channel EEG with ERP for Go/NoGo and Prospective Memory (PM) tasks for selected patients

DIAGNOSTIC_TEST

Amyloid PET CT

F18 Flutametamol PET CT for selected patients

Sponsors & Collaborators

  • Dementias Platform UK

    collaborator UNKNOWN

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Joseph SK Kwan, MD · The University of Hong Kong

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-01
Primary Completion
2022-01-01
Completion
2022-01-04

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03275363 on ClinicalTrials.gov